(Q36780542)

16 August 2017

1 reference

title

The Ras/Raf/MAPK pathway (English)

1 reference

16 August 2017

The Ras/Raf/MAPK Pathway (English)

0 references

2

Alex A Adjei

1 reference

16 August 2017

1

Julian R Molina

1 reference

16 August 2017

1

Julian R. Molina

0 references

author name string

Alex A. Adjei

series ordinal

2

0 references

publication date

1 January 2006

1 reference

Journal of Thoracic Oncology

16 August 2017

January 2006

0 references

published in

1 reference

16 August 2017

1

1 reference

16 August 2017

7-9

1 reference

16 August 2017

1

1 reference

Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

The epidermal growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

Ras activation in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

Blocking oncogenic Ras signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

1 reference

7 January 2021

Inhibitors of the ras oncogene as therapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

GTPases and T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

Cell signaling by receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

1 reference

7 January 2021

MEKK1 binds raf-1 and the ERK2 cascade components

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

Implications and prognostic value of K-ras mutation for early-stage lung cancer in women

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931506-9

7 January 2021

10.1016/S1556-0864(15)31506-9

Identifiers

DOI

0 references

1 reference